Overview

Efficacy and Safety of Aliskiren 75 mg, 150 mg, and 300 mg in Elderly Patients With Essential Hypertension When Given With a Light Meal in a 8 Week Placebo-controlled Study

Status:
Completed
Trial end date:
2009-04-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the efficacy and safety of aliskiren 75 mg, 150 mg, and 300 mg in elderly patients with essential hypertension when given with a light meal.
Phase:
Phase 3
Details
Lead Sponsor:
Novartis